Axis Granted Review of Arecont Multi-Imager: 'More Likely Than Not' 'Unpatentable'

By Brian Karas, Published Jan 09, 2018, 09:25am EST (Info+)

In 2016, Arecont publicly threatened Axis [link no longer available] with infringing on their multi-imager patent.

In 2017, Axis responded by filing a challenge in US court for Arecont's patent.

Now, the USPTO has seen merit in Axis' claim, granting their request for a post grant review, which is done on the basis it is "more likely than not" that at least one claim of a patent is actually unpatentable.

In this update, we examine the current status of the case, timeline, steps to a final resolution, and how losing this patent could affect Arecont.

Summary ** ***** ******* ********

** * ******** ****** ** *** ****** ******, *** ** *** ** ****** made ** *******'* ******** ****** **** deemed ** ** *********** ************. **** decision ** ***** ** ****** ** prior *** *** ***** ******** ******** by **** ** ***** *********:

***** ** **** ********, *** ****** challenge ***** ** ** * *****, *** ultimately * ***** ******** **** **** uphold, ** **********, *******'* ****** ******.

Axis ************ *********

**** ****** *******'* ****** ** ******* under** **** ***** **/******* ***, ***** ****** *** ******** ** "obvious" ***** ** ***** ***/******** *******. **** submitted ** ******** ******* **** ******** of **** ***** ***, ******* ******** challenges ** **** ** *** ** claims ** ************* ******* **** ** its ******* ****** ***********. ******* ***** for***** *****-****** ****** ** ***** ****. **** ** ****' ****** ** prior *** *******:

******* **** *** ****** *** "*******" ** a "******* *******", ** ****** *********** in ****** ******** ** ******** **** the ****** ******* **** ***** **** been ******* ** ** *** ****** skilled ** *** *** ** ***** such ******* (**** **** ********* ********* would *** *** "*********" ********* *** such ********). **** ***** ** ************, because *** ****** ** ********* *** unique ****** ** ******* * ****** and ***** **** **** ********* ** any ********* ********.

Next *****

* ********** ***** ******** * ****** ** * *** dates *** ********* *** **** **** and ******* ** ******* *** ****** further, *** ** ****** ********** ********* or ********** ** ***** ******. ***** due ***** *** ***** ****** ******** ************* for ******* ** ****** ***** ******, and *** **** ** ******* ** any ********** ****** ** *********** ******** by *******.

*** ** *** *** ***** *** of ********** ********:

*** **** *: ******** **, **** - ******* *** ***** **** **** to ******* ***** ******** ** *** petition ** **** *** ******* ** amend *** ******. ** ***, **** have *** ******** *** ********** ********, though **** **** ******* ***** **** to ** **. *******'* ********, ** lack ** ***, **** ****** *** the ****, *** ************, *** *** rest ** *** *******. *** ****** a ******** ** * ****-********* **** the ****** ** *** *****.

*** **** *: ****** **, **** - ***** **** ********* **** ** front ** ****** ****** *****, **** a ******** ***** ****** ** ** shortly ***** **** ****.

Arecont ********

******* ******* *** ********* ********* ** relation ** **** **** ********** ** trial:

*********, ** *** ******* ** ******* our ******* *********** ********* *** *******.  However, * **** ** ******* ********* any ******** **********.

Impact ** ****** ***********

****** ***** ****** *********** ***** ********** affect *** ******* ********* ** *** company, ************ ** ******* ******* ** seek * *** ***** ***** ***** ******** ********* **** **** *******. ****, **** ***** ********* *** possibility ** ******* ******* ****** ******* revenue ******** ** **** ******** *** been ***** **** *** **** *** years.

*******, * **** ** *** ****** is unlikely ** *** *** ******* ** significant ********** **** ** *********** ******* encroaching ** ***** *****-****** ****** *****. Several ***** ********* **** ******* ******* multi-imager ******* (*.*.********, ****,*****, ******, *********). *******, *******' *** ******* ******** and **** ********** ******** ** **** it ******* *** **** ****** ****** in *** *****-****** *****.

***** *** ***** ****** ************ ******** could **** *******'* ***** ****-*** / exit ********, *** ****** ** **** space ******* ***** **** *** ****** impact ****** ** *****.

Comments (0)

Login to read this IPVM report.
Why do I need to log in?
IPVM conducts reporting, tutorials and software funded by subscriber's payments enabling us to offer the most independent, accurate and in-depth information.
Loading Related Reports